Cite
MLA Citation
H Gogas et al.. “60PResponse rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials.” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095518057.0x000045